

## RESEARCH ARTICLES

## HEART DISEASE

# Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Paolo Zanoni,<sup>1\*</sup> Sumeet A. Khetarpal,<sup>1\*</sup> Daniel B. Larach,<sup>1\*</sup> William F. Hancock-Cerutti,<sup>1,2</sup> John S. Millar,<sup>1</sup> Marina Cuchel,<sup>1</sup> Stephanie DerOhannessian,<sup>1</sup> Anatol Kontush,<sup>2</sup> Praveen Surendran,<sup>3</sup> Danish Saleheen,<sup>3,4,5</sup> Stella Trompet,<sup>6,7</sup> J. Wouter Jukema,<sup>7,8</sup> Anton De Craen,<sup>6</sup> Panos Deloukas,<sup>9</sup> Naveed Sattar,<sup>10</sup> Ian Ford,<sup>11</sup> Chris Packard,<sup>12</sup> Abdullah al Shafi Majumder,<sup>13</sup> Dewan S. Alam,<sup>14</sup> Emanuele Di Angelantonio,<sup>3</sup> Goncalo Abecasis,<sup>15</sup> Rajiv Chowdhury,<sup>3</sup> Jeanette Erdmann,<sup>16</sup> Børge G. Nordestgaard,<sup>17</sup> Sune F. Nielsen,<sup>17</sup> Anne Tybjaerg-Hansen,<sup>18</sup> Ruth Frikke Schmidt,<sup>19</sup> Kari Kuulasmaa,<sup>20</sup> Dajiang J. Liu,<sup>21</sup> Markus Perola,<sup>20,22</sup> Stefan Blankenberg,<sup>23,24</sup> Veikko Salomaa,<sup>20</sup> Satu Männistö,<sup>20</sup> Philippe Amouyel,<sup>25</sup> Dominique Arveiler,<sup>26</sup> Jean Ferrieres,<sup>27</sup> Martina Müller-Nurasyid,<sup>28,29</sup> Marco Ferrario,<sup>30</sup> Frank Kee,<sup>31</sup> Cristen J. Willer,<sup>32</sup> Nilesh Samani,<sup>33,34</sup> Heribert Schunkert,<sup>35</sup> Adam S. Butterworth,<sup>3</sup> Joanna M. M. Howson,<sup>3</sup> Gina M. Peloso,<sup>36</sup> Nathan O. Stitzel,<sup>37</sup> John Danesh,<sup>3,9</sup> Sekar Kathiresan,<sup>36</sup> Daniel J. Rader,<sup>1†</sup> CHD Exome+ Consortium,<sup>‡</sup> CARDIoGRAM Exome Consortium, Global Lipids Genetics Consortium

Scavenger receptor BI (SR-BI) is the major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C). In humans, high amounts of HDL-C in plasma are associated with a lower risk of coronary heart disease (CHD). Mice that have depleted *Scarb1* (SR-BI knockout mice) have markedly elevated HDL-C levels but, paradoxically, increased atherosclerosis. The impact of SR-BI on HDL metabolism and CHD risk in humans remains unclear. Through targeted sequencing of coding regions of lipid-modifying genes in 328 individuals with extremely high plasma HDL-C levels, we identified a homozygote for a loss-of-function variant, in which leucine replaces proline 376 (P376L), in *SCARB1*, the gene encoding SR-BI. The P376L variant impairs posttranslational processing of SR-BI and abrogates selective HDL cholesterol uptake in transfected cells, in hepatocyte-like cells derived from induced pluripotent stem cells from the homozygous subject, and in mice. Large population-based studies revealed that subjects who are heterozygous carriers of the P376L variant have significantly increased levels of plasma HDL-C. P376L carriers have a profound HDL-related phenotype and an increased risk of CHD (odds ratio = 1.79, which is statistically significant).

**T**he strong inverse association between amounts of high-density lipoprotein (HDL) cholesterol (HDL-C) and coronary heart disease (CHD) risk has generated interest in a potential causal relationship between HDL metabolism and CHD. However, clinical trials with drugs that raise HDL-C levels, niacin and cholesteryl ester transfer protein (CETP) inhibitors, have produced disappointing results (1). Furthermore, recent studies of human genetic variants that are associated with HDL-C levels have generally failed to show association with CHD (2, 3). Most notably, a loss-of-function variant in *LIPG*, a gene encoding an endothelial lipase that, in the heterozygous state, raises HDL-C by ~5 mg/dl, was found to have no association with CHD (4). Although these previous studies suggest that higher HDL-C levels may not be causally protective against CHD, we reasoned that additional human genetic analyses might

provide mechanistic insight into the complex relationship between HDL and CHD.

The scavenger receptor class BI (SR-BI), encoded by the gene *SCARB1*, was discovered to be an HDL receptor two decades ago (5). SR-BI promotes the selective uptake of HDL cholesteryl esters (HDL-CEs) into cells, particularly hepatocytes and steroidogenic cells (5, 6). In mice, overexpression of SR-BI in the liver reduces levels of HDL-C (7–10), and genetic deletion of SR-BI results in higher HDL-C levels (11–13). Remarkably, these genetic manipulations in mice have effects on atherosclerosis opposite to those predicted by human epidemiological data: Overexpression reduces atherosclerosis despite the lower HDL-C levels (14–16), and gene deletion increases atherosclerosis despite the higher HDL-C levels (17–20). One potential explanation relates to the flux of cholesterol from macrophages through the reverse cholesterol transport (RCT) pathway; SR-BI

overexpression increases macrophage RCT, and SR-BI knockout reduces macrophage RCT (21). The human relevance of these observations has been unclear.

## Identification of *SCARB1* P376L homozygote and association with extremely high HDL-C

We hypothesized that humans with extremely high levels of HDL-C may harbor loss-of-function variants in *SCARB1* and undertook a targeted resequencing discovery experiment in 328 participants with very high HDL-C (>95th percentile, mean HDL-C of 106.8 mg/dl) and a control group of 398 subjects with low HDL-C (<25th percentile, mean HDL-C of 30.4 mg/dl). In this cohort, we sequenced the exons of ~990 genes located within 300 kb of each of the 95 loci with significant associations ( $P < 5 \times 10^{-8}$ ) with plasma lipid levels identified by the Global Lipids Genetics Consortium as of 2010 (22). Among the high HDL-C subjects, we identified a homozygote for *SCARB1* P376L (g.125284671 G>A, c.1127 C>T, p.P376L, rs74830677), a 67-year-old female with an HDL-C of 152 mg/dl, and confirmed this finding by Sanger sequencing. This subject harbored no mutations in other high HDL-C genes such as *CETP* and *LIPG*. In addition to this homozygote, four P376L heterozygotes were identified by targeted sequencing in the high HDL-C group; no heterozygotes were found in the low HDL-C group ( $P = 0.008$ , Fisher's exact test).

To identify additional P376L carriers, we genotyped an expanded cohort of very high versus low HDL-C subjects. Among 524 additional subjects with very high HDL-C (mean HDL-C 95.0 mg/dl), we identified 11 heterozygotes for P376L; whereas among 758 subjects with low HDL-C (mean HDL-C 33.5 mg/dl), we identified 3 heterozygotes. In total, our combined sequencing and genotyping for discovery of the P376L variant showed that this variant is significantly overrepresented in subjects with high HDL-C [minor allele frequency (MAF) = 0.010 in high HDL-C versus 0.0013 in low HDL-C controls,  $P = 0.000127$ , Fisher's exact test, Table 1].

Because this variant is present on the exome array, we expanded our analysis to the Global Lipid Genetics Consortium exome array data in >300,000 individuals. The P376L variant was very rare in this population (MAF of ~0.0003). It was significantly associated with higher HDL-C levels with a relatively large effect size (beta = 8.4 mg/dl;  $P = 1.4 \times 10^{-15}$ ). Notably, this variant was not associated with plasma levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides (TGs) (table S1). Thus, we conclude that *SCARB1* P376L is associated specifically with elevated HDL-C levels.

## HDL-related phenotypes of *SCARB1* P376L homozygote and heterozygotes

We next recruited the P376L homozygote, eight heterozygous carriers, and both high HDL-C and normal HDL-C noncarrier controls for deep phenotyping of HDL metabolism and related traits. All of the P376L study participants were of

European ancestry, almost exclusively of Ashkenazi Jewish descent. Clinical characteristics and lipid profiles of the subjects are reported in Table 2. Fast protein liquid chromatography (FPLC) analysis of plasma lipoproteins confirmed the increase in large HDL particles in the homozygote (Fig. 1A). Cholesterol and apolipoprotein A-I (apoA-I) levels in HDL were significantly increased in the homozygote and heterozygotes

compared with controls, but HDL apoA-II levels were not elevated (Table 2 and Fig. 1B). There were no differences between P376L carriers and controls in the absolute amount of HDL free cholesterol or the ratio of free-to-esterified cholesterol in their HDL (Fig. 1C). P376L heterozygotes had a 2.8-fold increase and the homozygote a 6.1-fold increase in large HDL-2b particles compared with noncarrier controls (Fig. 1D). There was more apoA-I (Fig. 1E and fig. S2) and apoC-III (Fig. 1F) in large HDL particles in the homozygote and heterozygous carriers. Cholesterol efflux capacity was similar in carriers and controls (Fig. 1G). In contrast to the infertility phenotype of *Scarb1*-deficient female mice (18), the P376L homozygote had two healthy children and reported no fertility impairment. We also did not observe the steroidogenic or platelet phenotypes reported in *Scarb1*-deficient mice (see supplementary materials).

### SCARB1 P376L results in complete loss of function of SR-BI

Given the profound HDL phenotype of the P376L carriers, we sought to understand the impact of the variant on SR-BI function. We generated induced pluripotent stem cells (iPSCs) using peripheral blood mononuclear cells from the P376L homozygote and a noncarrier control. We next differentiated these cells into hepatocyte-like cells (HLCs) to study HDL metabolism in the setting of endogenous cellular *SCARB1* expression. HLCs differentiated through this protocol recapitulate phenotypes of cultured primary hepatocytes such as albumin and VLDL (very low density lipoprotein) secretion (23–26). The cell lines from the control donor and the P376L homozygous subject demonstrated expression of hepatocyte-specific genes *ALB* (albumin) and *AFP* (alpha-fetoprotein) and exhibited comparable *SCARB1* gene expression (fig. S3). Compared with control iPSC hepatocyte lines, those from the P376L homozygote demonstrated a profound reduction in selective cholesterol uptake from HDL in vitro (Fig. 2A). Similar results were observed in experiments with COS7 cells transfected with plasmids expressing wild-type (WT) or the P376L variant of *SCARB1* (fig. S3,

A and B), along with defective binding to HDL in vitro at 4°C (fig. S4, C and D).

To evaluate the physiological impact of the P376L variant on HDL-C levels and catabolism in vivo, we used adeno-associated virus (AAV) vectors to direct hepatic overexpression of WT SR-BI or the P376L variant in mice with depleted *Scarb1* [*Scarb1* knockout (KO) mice]. The two groups of mice demonstrated similar hepatic expression levels of *Scarb1* mRNA (fig. S5A) and SR-BI protein (fig. S5B). Mice expressing WT *Scarb1* demonstrated a robust 73% decrease in HDL-C. In contrast, mice expressing the P376L variant had no reduction in HDL-C; their HDL-C levels were comparable to those in the control AAV-null injected mice (Fig. 2B). Although the clearance of <sup>125</sup>I-labeled HDL protein was not different among the three groups, the clearance of [<sup>3</sup>H]HDL-CE was much slower in mice expressing the P376L variant compared with those expressing WT SR-BI and was comparable to that in the control mice (Fig. 2, C and D). Selective HDL-CE clearance from plasma was increased by WT SR-BI but was undetectable in the P376L-expressing mice (Fig. 2E and fig. S5C), as was hepatic uptake of [<sup>3</sup>H]CE at 24 hours (fig. S5D). This indicates that the P376L sequence variant results in complete loss of the canonical function of SR-BI—namely, selective uptake of HDL-CE.

We hypothesized that the markedly reduced HDL-CE uptake could be because of aberrant processing of the P376L SR-BI protein, which leads to impaired cell surface localization. To test this, we isolated cell surface proteins from COS7 cells transfected with WT and P376L SR-BI using biotinylation and found markedly reduced cell surface SR-BI in the P376L transfected cell lysates after streptavidin cell surface protein pull-down assays (fig. S4E). Given that SR-BI undergoes N-glycosylation in the endoplasmic reticulum concomitant with proper folding, we hypothesized that altered posttranslational modification may underlie its reduced cell surface localization (27–29). We measured the molecular weights of SR-BI forms after endoglycosidase-H (Endo-H) treatment of transfected COS7 (fig. S4E) and iPSC-derived HLC

<sup>1</sup>Departments of Genetics and Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

<sup>2</sup>INSERM UMR 1166 ICAN, Université Pierre et Marie Curie Paris 6, Hôpital de la Pitié, Paris, France. <sup>3</sup>Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. <sup>4</sup>Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. <sup>5</sup>Centre for Non-Communicable Diseases, Karachi, Pakistan.

<sup>6</sup>Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, Netherlands. <sup>7</sup>Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands. <sup>8</sup>The Interuniversity Cardiology Institute of the Netherlands, Utrecht, Netherlands. <sup>9</sup>Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK. <sup>10</sup>Institute of Cardiovascular and Medical Sciences, British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

<sup>11</sup>Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK. <sup>12</sup>Glasgow Clinical Research Facility, Western Infirmary, Glasgow, UK. <sup>13</sup>National Institute of Cardiovascular Diseases, Sher-e-Bangla Nagar, Dhaka, Bangladesh.

<sup>14</sup>International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh. <sup>15</sup>Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. <sup>16</sup>Institute for Integrative and Experimental Genomics, University of Lübeck, Lübeck 23562, Germany. <sup>17</sup>Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. <sup>18</sup>Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark. <sup>19</sup>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark. <sup>20</sup>Department of Health, National Institute for Health and Welfare, Helsinki, Finland. <sup>21</sup>Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA. <sup>22</sup>Institute of Molecular Medicine FIMM, University of Helsinki, Helsinki, Finland. <sup>23</sup>Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany.

<sup>24</sup>University Medical Center Hamburg-Eppendorf, Hamburg, Germany. <sup>25</sup>Department of Epidemiology and Public Health, Institut Pasteur de Lille, Lille, France. <sup>26</sup>Department of Epidemiology and Public Health, University of Strasbourg, Strasbourg, France. <sup>27</sup>Department of Epidemiology, Toulouse University-CHU Toulouse, Toulouse, France. <sup>28</sup>Institute of Genetic Epidemiology, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. <sup>29</sup>Department of Medicine I, Ludwig-Maximilians-University Munich, Munich, Germany. <sup>30</sup>Research Centre in Epidemiology and Preventive Medicine, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.

<sup>31</sup>UKCRC Centre of Excellence for Public Health, Queens University, Belfast, Northern Ireland. <sup>32</sup>Department of Computational Medicine and Bioinformatics, Department of Human Genetics, and Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. <sup>33</sup>Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. <sup>34</sup>National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Unit, Glenfield Hotel, Leicester, UK. <sup>35</sup>Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. <sup>36</sup>Broad Institute and Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA. <sup>37</sup>Department of Medicine, Division of Cardiology, Department of Genetics, and the McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO 63110, USA.

<sup>38</sup>These authors contributed equally to this work. <sup>†</sup>Corresponding author. E-mail: rader@mail.med.upenn.edu <sup>‡</sup>For each consortium and study, authors and affiliations are listed in the supplementary materials.


**Table 1. Association of *SCARB1* P376L with HDL-C in high versus low HDL-C cohorts.** Carriers of the P376L variant were ascertained from the Penn High HDL Study through two approaches, targeted sequencing of the *SCARB1* gene in a total of 726 subjects (328 high HDL-C and 398 low HDL-C subjects) and genotyping on the exome array (Illumina) in an additional 1282 subjects (524 high HDL-C subjects and 758 low HDL-C subjects). The association of the P376L variant with the high HDL-C cohort from both approaches individually and combined together was tested using Fisher's exact test. N, number of participants; NonC, noncarriers; Het, heterozygotes; Hom, homozygotes.

| Discovery cohort                        | High HDL-C<br>(>95th percentile) (N) |      |     |     | Low HDL-C<br>(<25th percentile) (N) |      |     |     | Association<br>(P) |
|-----------------------------------------|--------------------------------------|------|-----|-----|-------------------------------------|------|-----|-----|--------------------|
|                                         | Total                                | NonC | Het | Hom | Total                               | NonC | Het | Hom |                    |
| Targeted sequencing<br>of <i>SCARB1</i> | 328                                  | 323  | 4   | 1   | 398                                 | 398  | 0   | 0   | 0.008398           |
| Exome array genotyping                  | 524                                  | 513  | 11  | 0   | 758                                 | 755  | 3   | 0   | 0.005296           |
| Combined                                | 852                                  | 836  | 15  | 1   | 1156                                | 1153 | 3   | 0   | 0.000127           |

lysates, as well as mouse liver lysates expressing WT or mutant SR-BI (Fig. 2, F and G). Higher-molecular-weight forms represent N-glycosylation modified Endo-H-resistant and partially sensitive forms at the cell surface after modification by alpha-mannosidase II in the Golgi apparatus (28).

In the iPSC-derived differentiated HCLs from the P376L homozygote (Fig. 2F), we found much less total cellular SR-BI in the mutant cell lines relative to that of WT cells, despite comparable *SCARB1* gene expression (fig. S3C). After Endo-H treatment, the SR-BI from *SCARB1* WT cell and liver lysates

across models was predominantly the partially sensitive form, along with small amounts of the fully resistant form. In contrast, the SR-BI from cell and tissue lysates across P376L-expressing groups was all the immature, fully Endo-H-sensitive form (Fig. 2, F and G, and fig. S4F). Together, these data



**Fig. 1. HDL composition and functionality in a *SCARB1* P376L homozygote, heterozygous carriers, and controls.** (A) FPLC fractionation of plasma lipoproteins from the P376L homozygote subject (red) and from a control with normal HDL-C. (B) Cholesterol, apoA-I, and apoA-II content in total HDL. (C) Free cholesterol (FC) and esterified cholesterol (CE) in total HDL (left) and the FC/CE ratio in total HDL (right). (D) HDL subclass concentrations after separation by density-gradient ultracentrifugation. (E) ApoA-I content in the same HDL subclasses. (F) ApoC-III content in the same HDL subclasses. (G) Cholesterol efflux capacity from macrophages of the THP-1 cell line. All data are reported as means ± SD.

| Table 2. Characteristics of <i>SCARB1</i> P376L carriers and controls recruited for deep phenotyping. |              |              |              |           | Significance |               |
|-------------------------------------------------------------------------------------------------------|--------------|--------------|--------------|-----------|--------------|---------------|
| Measure                                                                                               | Group        |              |              | P376L Hom | Tested       | Groups        |
|                                                                                                       | 1            | 2            | 3            |           |              |               |
| Number of subjects                                                                                    | 11           | 10           | 8            | 1         |              | -             |
| Age (years)                                                                                           | 61.6 (9.7)   | 64.2 (12.5)  | 67.5 (15.3)  | 65        | n.s.         | -             |
| Sex (M/F)                                                                                             | 6/5          | 5/5          | 6/2          | 0/1       | n.s.**       | -             |
| BMI (kg/m <sup>2</sup> )                                                                              | 26.4 (2)     | 22.9 (1.3)   | 25.6 (3.9)   | 21        | *            | 1/2           |
| TC (mg/dl)                                                                                            | 185.8 (22.3) | 215.8 (29.9) | 228 (33.2)   | 280       | *            | 1/3           |
| Glucose (mg/dl)                                                                                       | 93.5 (2.9)   | 91.6 (7.0)   | 98.8 (5.3)   | 86        | n.s.         | -             |
| LDL-C (mg/dl)                                                                                         | 109.1 (17.3) | 97.4 (21.6)  | 116.6 (27.1) | 109       | n.s.         | -             |
| HDL-C (PTA) (mg/dl)                                                                                   | 51 (11.4)    | 110.1 (19.8) | 86.9 (19.9)  | 152       | *            | 1/2, 1/3, 2/3 |
| TG (mg/dl)                                                                                            | 121.2 (35)   | 71.5 (32.3)  | 99.5 (23.7)  | 57        | *            | 1/2           |
| Alcohol >1/day (n)                                                                                    | 4            | 4            | 2            | 0         | n.s.**       | -             |
| VLDL-C (mg/dl)                                                                                        | 26.9 (8.8)   | 19 (6.2)     | 23.1 (9.2)   | 13        | n.s.         | -             |
| Lp(a) (mg/dl)                                                                                         | 22.3 (18.8)  | 19 (22.7)    | 15.9 (21.2)  | 17        | n.s.         | -             |
| apoA-I (mg/dl)                                                                                        | 172.2 (33.3) | 241.7 (41.2) | 229.6 (36.1) | 327       | *            | 1/2, 1/3      |
| apoA-II (mg/dl)                                                                                       | 40.5 (7)     | 49.5 (11.5)  | 46.6 (5.5)   | 45        | n.s.         | -             |
| apoB (mg/dl)                                                                                          | 99.7 (13.4)  | 82.8 (17.1)  | 95.9 (18.2)  | 92        | n.s.         | -             |
| apoC-II (mg/dl)                                                                                       | 4.32 (1.55)  | 6.09 (2.69)  | 4.49 (2.17)  | 5.3       | n.s.         | -             |
| apoC-III (mg/dl)                                                                                      | 11.4 (4.3)   | 15.5 (6.9)   | 13.7 (2.7)   | 16.1      | n.s.         | -             |
| apoE (mg/dl)                                                                                          | 4.52 (0.89)  | 6.03 (1.86)  | 4.94 (1.12)  | 6.4       | *            | 1/2           |

are consistent with a model in which the P376L sequence variant alters the endogenous post-translational N-glycosylation of SR-BI to prevent either transit from the ER to the Golgi or further posttranslational modifications in the Golgi, which ultimately result in reduced cell surface expression.

### SCARB1 P376L is associated with increased risk of CHD in humans

Despite a profound increase in HDL-C, SR-BI deficiency in mice causes accelerated atherosclerosis (17–20). The relationship of reduced SR-BI function to atherosclerotic cardiovascular disease in humans has not been established. The P376L homozygous subject did not have clinical CHD, but her carotid intimal-medial thickness (cIMT) was 0.789 mm (left-right average), which is in the


>75th percentile for females of her age; in addition, she had detectable plaque throughout the left internal carotid artery and at the bifurcation of her right internal carotid artery. cIMT measurements were not significantly different in the P376L heterozygotes compared with both groups of controls (fig. S8), but because of small sample size, the statistical power is limited.

To achieve greater statistical power to address this question, we performed a meta-analysis of large exome array genotyping studies of CHD cases and healthy controls to determine the relationship of the P376L variant with risk of CHD (Table 3). Among 16 sample sets from two consortia [the CARDIOGRAM Exome Consortium and the CHD Exome+ Consortium], we tested the association between P376L carrier status and CHD in 137,995 individuals. Across 49,846 CHD cases and 88,149 CHD controls, we found that

P376L carriers had a significantly higher risk of CHD compared with noncarriers [odds ratio for disease among carriers = 1.79;  $P = 0.018$ ] (Table 3). Thus, carriers of this *SCARB1* P376L variant have significantly increased HDL-C levels and a significantly increased risk of CHD.

### Discussion

Studies of mice have provided important insights into the effects of SR-BI on HDL metabolism, RCT, and atherosclerosis. These studies revealed that overexpression of SR-BI reduces HDL-C (7–10) and reduces atherosclerosis (14–16), whereas gene deletion of SR-BI increases HDL-C (11–13) and accelerates atherosclerosis (17–20). The clinical relevance of these findings has remained uncertain, however. Studies of injected labeled HDL-CE in humans suggested that the majority of the HDL-CE was transported to the liver via



**Fig. 2. *SCARB1* P376L is a null variant in vitro and in vivo.** (A) [ $^3$ H] Cholesterol ether (CEt) uptake (left) and selective cholesterol uptake from HDL (right) in iPSC-derived HLCs from the P376L homozygote versus a noncarrier control. Cells were incubated with [ $^3$ H]CEt and [ $^{125}$ I]-labeled tyramine cellobiose (TC) dual-labeled human HDL. All values are normalized to relative *ALB* gene expression in each cell line. All data represent mean values for wells of respective cell lines  $\pm$  SD. (B) Plasma HDL cholesterol levels before and 12 days after AAV administration to *Scarb1* KO mice. (C) [ $^3$ H]Cholesterol ether (CEt) clearance (left) and fractional catabolic rate (right) from plasma of *Scarb1* KO mice injected with null or SR-BI AAVs after administration of [ $^3$ H]CEt/[ $^{125}$ I]-labeled TC dual-labeled human HDL. (D) [ $^{125}$ I]-labeled TC clearance (left) and fractional catabolic rate (right) from plasma after administration of dual-labeled HDL. (E) Selective cholesterol uptake in mice expressing null, SR-BI

WT, or P376L measured by relative differences in  $^3$ H- and [ $^{125}$ I]-labeled fractional catabolic rates. (F) Sensitivity to Endo-H in P376L homozygous versus noncarrier iPSC-derived HLCs. Cell lysates of each genotype were treated with Endo-H to remove complex N-linked glycans from mature forms of proteins and then immunoblotted for SR-BI. Molecular weights of different forms of SR-BI after Endo-H treatment are given on the left. (G) SR-BI Endo-H sensitivity from liver lysates from mice expressing null, SR-BI WT, or SR-BI P376L AAV. Lysates were treated with Endo-H, followed by immunoblotting for SR-BI. Molecular weights of different forms of SR-BI after Endo-H treatment are given on the left. (A) Mean values for wells of respective cell lines  $\pm$  SD; [(B) to (E)] means  $\pm$  SD for each of the three groups. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  by analysis of variance (ANOVA) [(B) and (C)]; plasma clearance, unpaired  $t$  test (E).

**Table 3. Meta-analysis of association of *SCARB1* P376L variant with CHD.** CHD cases and healthy controls across the CARDIoGRAM Exome Consortium and CHD Exome+ Consortium were genotyped for the *SCARB1* P376L variant by using the exome array. BioVU, Vanderbilt University Medical Center Biorepository; BHF, British Heart Foundation; GoDARTS-CAD, Genetics of Diabetes and Audit Research Tayside Study; MHI, Montreal Heart Institute; North German, German North Coronary Artery Disease Study; Ottawa, Ottawa Heart Study; PAS, Premature Atherosclerosis Study—Academic Medical Center—Amsterdam; Penn, University of Pennsylvania CHD Cohort; South German, German South

Coronary Artery Disease Study; WHI-EA, Women's Health Initiative—European American Cohort; CCHS, Copenhagen City Heart Study; CIHDS/CGPS, Copenhagen Ischemic Heart Disease Study/Copenhagen General Population Study; EPIC-CVD, European Prospective Investigation into Cancer and Nutrition—Cardiovascular Disease Study; MORGAM, MONica Risk, Genetics, Archiving and Monograph Project; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk Study; WOSCOPS, West of Scotland Coronary Prevention Study. The association of the P376L variant with CHD cases was determined using a Mantel-Haenszel fixed-effects meta-analysis; results were odds ratio = 1.79; *P* = 0.018.

| Consortium or study cohort  | P376L carriers |          | Total     |          | Frequency |          |
|-----------------------------|----------------|----------|-----------|----------|-----------|----------|
|                             | Cases          | Controls | CHD cases | Controls | Cases     | Controls |
| CARDIoGRAM Exome Consortium |                |          |           |          |           |          |
| BioVU                       | 6              | 10       | 4587      | 16546    | 0.0013    | 0.0006   |
| BHF                         | 1              | 0        | 2833      | 5912     | 0.0004    | 0        |
| GoDARTS-CAD                 | 1              | 0        | 1568      | 2772     | 0.0006    | 0        |
| MHI                         | 0              | 4        | 2483      | 8085     | 0         | 0.0005   |
| North German                | 0              | 1        | 4464      | 2886     | 0         | 0.0004   |
| Ottawa                      | 0              | 1        | 1024      | 2267     | 0         | 0.0004   |
| PAS                         | 1              | 1        | 728       | 808      | 0.0014    | 0.0012   |
| Penn                        | 3              | 0        | 683       | 156      | 0.0044    | 0        |
| South German                | 4              | 0        | 5255      | 2921     | 0.0008    | 0        |
| WHI-EA                      | 8              | 29       | 2860      | 14929    | 0.0028    | 0.0019   |
| CHD Exome+ Consortium       |                |          |           |          |           |          |
| CCHS                        | 1              | 1        | 2020      | 6087     | 0.0003    | 0.0001   |
| CIHDS/CGPS                  | 4              | 3        | 8079      | 10367    | 0.0003    | 0.0001   |
| EPIC-CVD                    | 4              | 2        | 9810      | 10970    | 0.0002    | 0.0001   |
| MORGAM                      | 0              | 0        | 2153      | 2118     | 0         | 0        |
| PROSPER                     | 1              | 0        | 640       | 638      | 0.0008    | 0        |
| WOSCOPS                     | 0              | 0        | 659       | 687      | 0         | 0        |
| Total                       | 34             | 52       | 49846     | 88149    | 0.00068   | 0.00059  |

CETP-mediated exchange to apoB-containing lipoproteins rather than by direct uptake from HDL by the liver (30), which brings into question the importance of hepatic SR-BI in human physiology. Common genetic variants near the *SCARB1* locus were found to be significantly associated with plasma HDL-C levels, which suggests that SR-BI may play a role in HDL metabolism in humans (22, 31). A family with a rare *SCARB1* variant in which serine replaces proline 297 (P297S) was reported in which the heterozygous carriers of the variant had modestly elevated HDL-C levels (31). However, the variant retains substantial SR-BI activity, no homozygotes were identified, the apparent effect on HDL-C was modest, and there was insufficient power to address its effects on atherosclerosis.

Through sequencing of subjects with extremely high plasma levels of HDL-C, we identified a homozygote for a P376L variant in SR-BI. Our complementary approaches consistently demonstrated that this variant confers virtually complete loss of function of SR-BI. Our results demonstrate many similarities in the consequences of SR-BI deficiency on HDL composition between mice and humans, including a shift toward large, buoyant HDL particles and a significant increase in apoA-I, but not apoA-II, in plasma and HDL (12, 32, 33). The homozygote is a woman who had two healthy

children without fertility issues or delivery complications, which suggests that, in humans, SR-BI deficiency may not impair reproductive function in the same manner as it does in mice (18, 34). In mice, SR-BI-mediated CE uptake from HDL is a critical process underlying steroid hormone synthesis in adrenal and gonadal tissues, and SR-BI deficiency alters adrenal cholesterol content, impairs adrenal glucocorticoid response under stress, and can lead to fasting-induced hypoglycemia (6, 35, 36). We did not observe any differences in fasting glucose, serum cortisol, adrenocorticotrophic hormone, or female gonadal hormones in P376L heterozygous subjects versus controls, and we saw only a modest increase in testosterone in male P376L heterozygotes relative to noncarriers. We postulate that differences in expression or capacity for up-regulation of apoB-containing lipoprotein receptors relative to SR-BI between mouse models and humans in steroidogenic tissues may account, at least partially, for the lack of recapitulation of some of the phenotypes of SR-BI deficiency in mice. We also observed no differences in platelet levels, cholesterol content, and activation from the P376L carriers, despite reports of thrombocytopenia and altered platelet activity in *Scarb1* KO mice (31). These results suggest a relatively different contribution of SR-BI to platelet function between mice and humans. Note

that the phenotypes of human *SCARB1* P376L homozygote (elevated HDL-C and large HDL particles but relatively normal steroidogenesis, reproductive viability, and platelet function) are comparable to those observed in mice lacking PDZ domain containing 1 (PDZK1), an adaptor protein for SR-BI (37).

Perhaps the most important finding of our study is that, despite the elevation in HDL-C, P376L carriers exhibit increased risk of CHD, as do *Scarb1* KO mice. Our results are consistent with a growing theme in HDL biology that steady-state concentrations of HDL-C are not causally protective against CHD and that HDL function and cholesterol flux may be more important than absolute levels. Using an in vivo assay of macrophage RCT, we previously showed that *Scarb1* KO mice have impaired macrophage RCT even though they have elevated HDL-C levels (21). Our results suggest that reduced hepatic SR-BI function in humans causes impaired RCT, which leads to increased risk of CHD despite elevation in HDL-C levels. However, SR-BI is also expressed in vascular cell types, including endothelial cells, vascular smooth muscle cells, and macrophages, where it could have protective effects against atherosclerosis as well (38, 39). Our results are also consistent with the previously suggested concept (39) that up-regulation or enhancement of SR-BI

could be a novel therapeutic approach to reducing CHD risk in the general population.

## REFERENCES AND NOTES

1. D. J. Rader, A. R. Tall, *Nat. Med.* **18**, 1344–1346 (2012).
2. C. L. Haase et al., *J. Clin. Endocrinol. Metab.* **97**, E248–E256 (2012).
3. R. Frikke-Schmidt et al., *JAMA* **299**, 2524–2532 (2008).
4. B. F. Voight et al., *Lancet* **380**, 572–580 (2012).
5. S. Acton et al., *Science* **271**, 518–520 (1996).
6. M. Hoekstra, T. J. Van Berkel, M. Van Eck, M. Krieger, *J. Gastroenterol.* **16**, 5916–5924 (2010).
7. N. Wang, T. Arai, Y. Ji, F. Rinninger, A. R. Tall, *J. Biol. Chem.* **273**, 32920–32926 (1998).
8. Y. Ueda et al., *J. Biol. Chem.* **274**, 7165–7171 (1999).
9. K. F. Kozarsky et al., *Nature* **387**, 414–417 (1997).
10. Y. Ji et al., *J. Biol. Chem.* **274**, 33398–33402 (1999).
11. M. L. Varban et al., *Proc. Natl. Acad. Sci. U.S.A.* **95**, 4619–4624 (1998).
12. A. Rigotti et al., *Proc. Natl. Acad. Sci. U.S.A.* **94**, 12610–12615 (1997).
13. M. Brundert et al., *Arterioscler. Thromb. Vasc. Biol.* **25**, 143–148 (2005).
14. Y. Ueda et al., *J. Biol. Chem.* **275**, 20368–20373 (2000).
15. K. F. Kozarsky, M. H. Donahee, J. M. Glick, M. Krieger, D. J. Rader, *Arterioscler. Thromb. Vasc. Biol.* **20**, 721–727 (2000).
16. T. Arai, N. Wang, M. Bezouevski, C. Welch, A. R. Tall, *J. Biol. Chem.* **274**, 2366–2371 (1999).
17. M. Van Eck et al., *J. Biol. Chem.* **278**, 23699–23705 (2003).
18. B. Trigatti et al., *Proc. Natl. Acad. Sci. U.S.A.* **96**, 9322–9327 (1999).
19. D. Huszar et al., *Arterioscler. Thromb. Vasc. Biol.* **20**, 1068–1073 (2000).
20. A. Braun et al., *Circ. Res.* **90**, 270–276 (2002).
21. Y. Zhang et al., *J. Clin. Invest.* **115**, 2870–2874 (2005).
22. T. M. Teslovich et al., *Nature* **466**, 707–713 (2010).
23. A. Ghodizadeh et al., *Stem Cell Rev.* **6**, 622–632 (2010).
24. M. A. Cayo et al., *Hepatology* **56**, 2163–2171 (2012).
25. S. K. Mallanna, S. A. Duncan, *Curr. Protocol Stem Cell Biol.* **26** (Unit 16), 4 (2013).
26. K. Si-Tayeb et al., *Hepatology* **51**, 297–305 (2010).
27. J. Babbitt et al., *J. Biol. Chem.* **272**, 13242–13249 (1997).
28. M. Viñals, S. Xu, E. Vasilie, M. Krieger, *J. Biol. Chem.* **278**, 5325–5332 (2003).
29. D. Calvo, D. Gómez-Coronado, M. A. Lasunción, M. A. Vega, *Arterioscler. Thromb. Vasc. Biol.* **17**, 2341–2349 (1997).
30. C. C. Schwartz, J. M. VandenBroek, P. S. Cooper, *J. Lipid Res.* **45**, 1594–1607 (2004).
31. M. Vergeer et al., *N. Engl. J. Med.* **364**, 136–145 (2011).
32. R. B. Hildebrand et al., *Arterioscler. Thromb. Vasc. Biol.* **30**, 1439–1445 (2010).
33. L. Lagrost et al., *Arterioscler. Thromb.* **13**, 815–825 (1993).
34. H. E. Miettinen, H. Rayburn, M. Krieger, *J. Clin. Invest.* **108**, 1717–1722 (2001).
35. M. Hoekstra et al., *J. Lipid Res.* **49**, 738–745 (2008).
36. M. Hoekstra et al., *J. Lipid Res.* **50**, 1039–1046 (2009).
37. O. Koecher et al., *J. Biol. Chem.* **278**, 52820–52825 (2003).
38. C. Mineo, P. W. Shaul, *Curr. Opin. Lipidol.* **23**, 487–493 (2012).
39. A. Rigotti, H. E. Miettinen, M. Krieger, *Endocr. Rev.* **24**, 357–387 (2003).

## ACKNOWLEDGMENTS

We appreciate the participation and support of participants of the deep clinical phenotyping studies. We thank E. Mohler for assistance in interpretation of cIMT results and J. Billheimer and E. Pashos for helpful discussions. We also acknowledge J. Tabita-Martinez for expert assistance with clinical phenotyping studies. This work was supported in part by an award from the National Center for Research Resources (grant TLIR024133) and National Center for Advancing Translational Sciences of the NIH (grant TLIR000138) to support patient recruitment. D.B.L. was supported by a fellowship from the Doris Duke Charitable Foundation. S.K. has financial relationships with Novartis, Aegerion, Bristol-Myers Squibb, Sanofi, AstraZeneca, Alnylam, Eli Lilly, Leerik Partners, Merck, Catabasis, Regeneron Genetic Center, San Therapeutics, and Celera. H.S. has financial relationships with MSD Sharp and Dohme, Sanofi-Aventis, and Amgen. S.B. has financial relationships with Boehringer Ingelheim, Bayer, Novartis, Roche, and Thermo Fisher. N.S. has financial relationships with Amgen, Sanofi, AstraZeneca, and MSD Sharp and Dohme. A.K. has a financial relationship with Amgen. J.D. has a financial relationship with Novartis. A.T.-H. has financial relationships with Eli Lilly and LGC Genomics. Sequencing data have been deposited in GenBank (SRX1458096).

Genotyping data have been deposited in the Gene Expression Omnibus (GSE76065).

## SUPPLEMENTARY MATERIALS

www.sciencemag.org/content/351/6278/1166/suppl/DC1  
Materials and Methods  
Supplementary Text

Figs. S1 to S7  
Table S1  
References (40–76)  
Consortia and Study Author Lists

1 September 2015; accepted 7 January 2016  
10.1126/science.aad3517

## CHEMICAL PHYSICS

# Wavelike charge density fluctuations and van der Waals interactions at the nanoscale

Alberto Ambrosetti,<sup>1,2</sup> Nicola Ferri,<sup>1</sup> Robert A. DiStasio Jr.,<sup>3,\*</sup> Alexandre Tkatchenko<sup>1,4,\*</sup>

Recent experiments on noncovalent interactions at the nanoscale have challenged the basic assumptions of commonly used particle- or fragment-based models for describing van der Waals (vdW) or dispersion forces. We demonstrate that a qualitatively correct description of the vdW interactions between polarizable nanostructures over a wide range of finite distances can only be attained by accounting for the wavelike nature of charge density fluctuations. By considering a diverse set of materials and biological systems with markedly different dimensionalities, topologies, and polarizabilities, we find a visible enhancement in the nonlocality of the charge density response in the range of 10 to 20 nanometers. These collective wavelike fluctuations are responsible for the emergence of nontrivial modifications of the power laws that govern noncovalent interactions at the nanoscale.

The assembly of complex nanostructures and biological systems from simpler building blocks is often driven by noncovalent van der Waals (vdW) or dispersion interactions that arise from electrodynamic correlations between instantaneous charge fluctuations in matter (1, 2). The influence of vdW forces extends well beyond binding energies and encompasses the structural (3, 4), mechanical (5, 6), spectroscopic (7), and even electronic (8) signatures of condensed matter. A common way to characterize vdW interactions is by power laws in the distance  $D$  between two or more objects (e.g., atoms, molecules, nanostructures, surfaces, or solids); the most familiar is arguably the Lennard-Jones potential, which is characterized by a short-range repulsive wall with a  $D^{-12}$  dependence and a long-range attractive tail with a  $D^{-6}$  dependence. Even a slight variation in these power laws can have a profound impact on observed properties and therefore demands an accurate, physically sound theoretical description.

Thus far, both our conceptual understanding of vdW interactions and the quantitative models widely used for describing these quantum mechanical phenomena are primarily rooted in low-order intermolecular perturbation theory (IPT), wherein


vdW binding originates from the interactions between transient local multipoles (9), and macroscopic Lifshitz theory (10). Although IPT-based approaches have had enormous success in describing vdW binding in (small) gas-phase molecular systems (11, 12), recent advanced experimental techniques have produced several findings that are challenging the basic assumptions of IPT and macroscopic approaches for nanostructured materials, and are strongly indicative that even our qualitative understanding of these interactions is incomplete and needs to be substantially revised (13). Examples of such experimental observations include (i) ultra-long-range vdW interactions extending up to tens of nanometers into heterogeneous dielectric interfaces (14, 15), (ii) complete screening of the vdW interaction between an atomic force microscope (AFM) tip and a SiO<sub>2</sub> surface by the presence of one or more layers of graphene adsorbed on the surface (16), (iii) super-linear sticking power laws for the self-assembly of metallic clusters on carbon nanotubes with increasing surface area (17), and (iv) nonlinear increases in the vdW attraction between homologous molecules and an Au(111) surface as a function of molecular size (18). Satisfactory theoretical explanations for these experimental findings either require ad hoc modifications to IPT [(iii) and (iv)] or are inherently outside the domain of applicability of IPT [(i) and (ii)].

To address these issues, we note that the spatial extent of the instantaneous charge density fluctuations responsible for vdW interactions depends rather sensitively on the nature and character of the occupied-to-virtual transitions of the

<sup>1</sup>Fritz-Haber-Institut der Max-Planck-Gesellschaft, D-14195 Berlin, Germany. <sup>2</sup>Dipartimento di Fisica e Astronomia, Università degli Studi di Padova, 35131 Padova, Italy.

<sup>3</sup>Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA. <sup>4</sup>Physics and Materials Science Research Unit, University of Luxembourg, L-1511 Luxembourg.

\*Corresponding author. E-mail: distasio@cornell.edu (R.A.D.); alexandre.tkatchenko@uni.lu (A.T.)



## Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Paolo Zanoni *et al.*

*Science* **351**, 1166 (2016);

DOI: 10.1126/science.aad3517

*This copy is for your personal, non-commercial use only.*

If you wish to distribute this article to others, you can order high-quality copies for your colleagues, clients, or customers by [clicking here](#).

Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines [here](#).

**The following resources related to this article are available online at [www.sciencemag.org](http://www.sciencemag.org) (this information is current as of March 14, 2016 ):**

**Updated information and services**, including high-resolution figures, can be found in the online version of this article at:

</content/351/6278/1166.full.html>

**Supporting Online Material** can be found at:

</content/suppl/2016/03/09/351.6278.1166.DC1.html>

A list of selected additional articles on the Science Web sites **related to this article** can be found at:

</content/351/6278/1166.full.html#related>

This article **cites 74 articles**, 35 of which can be accessed free:

</content/351/6278/1166.full.html#ref-list-1>

This article appears in the following **subject collections**:

Medicine, Diseases

</cgi/collection/medicine>